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Dear Editor,
A 48-year-old man was incidentally found to have a
lymphocytosis, with haemoglobin: 14.1 g/dL, white cell
count: 16.6×109/L (77% abnormal lymphocytes), and
platelet count: 160×109/L. The abnormal lymphocytes
were small, with scanty basophilic cytoplasm showing
frequent blebs (Fig. 1a). The nuclei contained condensed
chromatin and inconspicuous nucleoli. They were predom-
inantly positive for CD4 (Fig. 1b), and expressed CD2,
CD5, CD7 and T cell receptor (TCR) αβ. Karyotyping
showed inv(14)(q11q32) with multiple karyotypic aberra-
tions (Fig. 1c). Serologic test for human T-lymphotropic
virus 1 was negative. The diagnosis was consistent with T-
prolymphocytic leukaemia (T-PLL) [1]. The patient elected
not to receive treatment. Eight months afterwards, he
presented with erythematous rashes, generalised lymphade-
nopathy and splenomegaly. A full blood count showed
haemoglobin: 10.9 g/dL, white cell count: 132×109/L (95%
abnormal lymphocytes), and platelet count: 139×109/L.
Interestingly, the lymphocytes showed a diminution in
CD4, but an increase in CD8 expression (CD4
+CD8–:23.9%, CD4–CD8+: 65.5%, CD4+CD8+: 10.6%;
Fig. 1d). Skin biopsy confirmed leukaemic infiltration. The
patient was treated with alemtuzumab (30 mg/day thrice
weekly) for 4 weeks without response. Two courses of
fludarabine, mitoxantrone, dexamethasone [2] and resump-
tion of alemtuzumab were ineffective. Immunophenotyping
11 months after diagnosis showed that the PLL cells were
predominantly CD8 expressing (CD4–CD8+:73.5%, and
CD4+CD8+:25.8%; Fig. 1e). Owing to the poor response to
alemtuzumab, CD52 expression was investigated. The PLL
cells had retained CD52 expression (Fig. 1f). To investigate
if a new clone might have emerged, polymerase chain
reaction for TCR gamma gene was performed. Identical
peaks were demonstrated despite a change from CD4 to
CD8 expression (Fig. 1g). Splenectomy was performed,
followed by combination chemotherapy (dexamethasone,
methotrexate, ifosphamide, etoposide, L-asparaginase).
However, the patient died of sepsis 2 weeks afterwards.
This case showed a number of interesting features
pertinent to the diagnosis of T-PLL. The usual morpholog-
ical features of prolymphocytes, viz., small to medium cells
with a single distinct nucleolus and abundant cytoplasm,
were not observed. The neoplastic cells were instead mature
looking. It has been proposed that a diagnosis of “mature T
cell leukaemia, unclassified” might be offered to such cases
[3]. However, had the case presented later when CD8
expression predominated, a diagnosis of T cell large
granular lymphocyte leukaemia might have been enter-
tained. These diagnostic difficulties were resolved with
demonstration of inv(14), implying that this case should be
classified as the small cell variant of T-PLL [1]. The
immunophenotypical switch from CD4 to CD8 was also
intriguing. Molecular analysis confirmed that the CD4 to
CD8 switch occurred in the same clone, implying that the
immunophenotypical switch was an intrinsic property of
the T-PLL cells. This phenomenon appeared to be excep-
tionally rare; and to our knowledge, only one similar case
had been reported, in which a change from CD4 to CD8
expression was associated with large cell transformation
[4]. Interestingly, the CD8+ phenotype had also been
reported to be associated with a poor response to
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Fig. 1 Pathological features of a
case of T-cell prolymphocytic
leukemia (PLL). a Abnormal
lymphoid cells at diagnosis,
showing condensed nuclei with
inconspicuous nucleoli, and
scanty basophilic cytoplasm with
frequent blebs (Wright–Giemsa
stain, original magnification
×100). b Flow cytometric analy-
sis at diagnosis, showing pre-
dominance of CD4+ PLL cells.
c Karotyping analysis, showing
inv(14)(q11q32) (arrow, insert)
and other aberrations. d At
8 months, there was an increase
in CD8+ PLL cells. e At
11 months, there was predomi-
nance of CD8+ PLL cells. f
CD52 expression had been
consistent through the clinical
course. g T cell receptor gene
gamma rearrangement studies,
showing identical peaks at
various time points in the clinical
course (GeneMapper v3.7,
Applied Biosystems)
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conventional chemotherapy [5]. Such observations were
recapitulated in our case, which showed a relentless
deterioration with increasing CD8 expression.
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